JP2009524419A - Ｌｎａ修飾したホスホロチオール化オリゴヌクレオチド - Google Patents

Ｌｎａ修飾したホスホロチオール化オリゴヌクレオチド Download PDF

Info

Publication number
JP2009524419A
JP2009524419A JP2008551732A JP2008551732A JP2009524419A JP 2009524419 A JP2009524419 A JP 2009524419A JP 2008551732 A JP2008551732 A JP 2008551732A JP 2008551732 A JP2008551732 A JP 2008551732A JP 2009524419 A JP2009524419 A JP 2009524419A
Authority
JP
Japan
Prior art keywords
lna
oligonucleotide
mixed sequence
rna
sequence oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008551732A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009524419A5 (enExample
Inventor
ヨアヒム・エルメン
ヘンリク・フリゼンルン・ハンセン
ヘンリク・エルム
トレルス・コッホ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Innovation Center Copenhagen AS
Original Assignee
Santaris Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santaris Pharma AS filed Critical Santaris Pharma AS
Publication of JP2009524419A publication Critical patent/JP2009524419A/ja
Publication of JP2009524419A5 publication Critical patent/JP2009524419A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008551732A 2006-01-27 2007-01-29 Ｌｎａ修飾したホスホロチオール化オリゴヌクレオチド Pending JP2009524419A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76292006P 2006-01-27 2006-01-27
PCT/EP2007/000741 WO2007085485A2 (en) 2006-01-27 2007-01-29 Lna modified phosphorothiolated oligonucleotides

Publications (2)

Publication Number Publication Date
JP2009524419A true JP2009524419A (ja) 2009-07-02
JP2009524419A5 JP2009524419A5 (enExample) 2010-03-11

Family

ID=38007090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008551732A Pending JP2009524419A (ja) 2006-01-27 2007-01-29 Ｌｎａ修飾したホスホロチオール化オリゴヌクレオチド

Country Status (7)

Country Link
US (1) US20090176977A1 (enExample)
EP (1) EP1984382B1 (enExample)
JP (1) JP2009524419A (enExample)
AU (1) AU2007209481B2 (enExample)
CA (1) CA2638837A1 (enExample)
DK (1) DK1984382T3 (enExample)
WO (1) WO2007085485A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018504380A (ja) * 2014-12-18 2018-02-15 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｒｅｖｅｒｓｉｒ（商標）化合物

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004221760B2 (en) 2003-03-21 2010-03-18 Roche Innovation Center Copenhagen A/S Short interfering RNA (siRNA) analogues
WO2005073378A1 (en) * 2004-01-30 2005-08-11 Santaris Pharma A/S MODIFIED SHORT INTERFERING RNA (MODIFIED siRNA)
ES2556128T3 (es) * 2006-03-23 2016-01-13 Roche Innovation Center Copenhagen A/S ARN interfiriente pequeño internamente segmentado
JP5723154B2 (ja) 2007-09-19 2015-05-27 アプライド バイオシステムズ リミテッド ライアビリティー カンパニー ＲＮＡｉにおけるオフターゲット表現型の影響を減少させるためのＳｉＲＮＡ配列非依存性修飾フォーマットおよびその安定化型
JP2010539961A (ja) * 2007-10-04 2010-12-24 サンタリス ファーマ アー／エス ＨＩＦ１αの調節のための短いＲＮＡアンタゴニスト化合物
ES2609655T3 (es) 2009-05-06 2017-04-21 Curna, Inc. Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
US20150025122A1 (en) 2009-10-12 2015-01-22 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
EP3214174B1 (en) 2010-03-04 2019-10-16 InteRNA Technologies B.V. A mirna molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with emt
EP2591106A1 (en) 2010-07-06 2013-05-15 InteRNA Technologies B.V. Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
US20140323557A1 (en) * 2011-11-11 2014-10-30 Santaris Pharma A/S Compounds for the modulation of beta-catenin expression and uses thereof
EP3369818B1 (en) 2011-12-22 2021-06-09 InteRNA Technologies B.V. Mirna for treating head and neck cancer
US10201556B2 (en) 2012-11-06 2019-02-12 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
CA2889044A1 (en) 2012-11-15 2014-05-22 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
WO2014140856A2 (en) 2013-03-15 2014-09-18 Graham Lord Mir-142 and antagonists thereof for treating disease
AU2014306271A1 (en) 2013-08-08 2016-03-24 The Scripps Research Institute A method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides
EP3129493B1 (en) 2014-04-09 2021-07-07 The Scripps Research Institute Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
EP3181698A1 (en) 2015-12-16 2017-06-21 European Molecular Biology Laboratory (EMBL) Microrna mir-142 as stem cell marker
TWI821192B (zh) 2017-07-11 2023-11-11 美商新索思股份有限公司 非天然核苷酸之導入及其方法
IL321812A (en) 2017-08-03 2025-08-01 Synthorx Inc Cytokine complexes for the treatment of autoimmune diseases
AU2018358016A1 (en) 2017-11-03 2020-05-07 Interna Technologies B.V. MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
WO2019155094A1 (en) 2018-02-12 2019-08-15 Interna Technologies B.V. Anticancer microrna and lipid formulations thereof
EP3802824A1 (en) 2018-06-05 2021-04-14 F. Hoffmann-La Roche AG Oligonucleotides for modulating atxn2 expression
BR112021000538A2 (pt) 2018-07-13 2021-04-06 F. Hoffmann-La Roche Ag Oligonucleotídeos para modular a expressão de rtel1
BR112021001756A2 (pt) * 2018-07-31 2021-05-11 Roche Innovation Center Copenhagen A/S oligonucleotídeos, oligonucleotídeo gapmer, sal farmaceuticamente aceitável, conjugado, composição farmacêutica, usos de um oligonucleotídeo, método para o tratamento ou profilaxia de uma doença, processo para a fabricação de um oligonucleotídeo e invenção
MA54952A (fr) 2019-02-06 2022-05-11 Synthorx Inc Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
JP7725370B2 (ja) 2019-04-03 2025-08-19 ブリストル－マイヤーズ スクイブ カンパニー Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用
CN114867856A (zh) 2019-12-19 2022-08-05 豪夫迈·罗氏有限公司 Saraf抑制剂用于治疗乙型肝炎病毒感染的用途
JP7634542B2 (ja) 2019-12-19 2025-02-21 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用
JP2023506540A (ja) 2019-12-19 2023-02-16 エフ． ホフマン－ラ ロシュ エージー． Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用
WO2021122921A1 (en) 2019-12-19 2021-06-24 F. Hoffmann-La Roche Ag Use of cops3 inhibitors for treating hepatitis b virus infection
WO2021122910A1 (en) 2019-12-19 2021-06-24 F. Hoffmann-La Roche Ag Use of sbds inhibitors for treating hepatitis b virus infection
EP4081639A1 (en) 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
EP4081217A1 (en) 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv
CN115551519A (zh) 2020-05-11 2022-12-30 基因泰克公司 用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法
CN115605592A (zh) 2020-05-11 2023-01-13 基因泰克公司（Us） 用于治疗神经系统疾病的补体组分c1r抑制剂以及相关的组合物、系统和使用它们的方法
CN115698290A (zh) 2020-05-11 2023-02-03 基因泰克公司 用于治疗神经系统疾病的补体组分4抑制剂以及使用它们的相关组合物、系统和方法
JP2023538630A (ja) 2020-08-21 2023-09-08 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用
EP4259642A1 (en) * 2020-12-08 2023-10-18 F. Hoffmann-La Roche AG Novel synthesis of phosphorodithioate oligonucleotides
AU2022384619A1 (en) 2021-11-11 2024-04-11 F. Hoffmann-La Roche Ag Pharmaceutical combinations for treatment of hbv
CN119095603A (zh) 2021-12-17 2024-12-06 豪夫迈·罗氏有限公司 用于调节rtel1和fubp1的寡核苷酸的组合
WO2025235462A1 (en) * 2024-05-06 2025-11-13 Gt Molecular, Inc. Selective blocking to detect and amplify low abundant template

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008518608A (ja) * 2004-11-09 2008-06-05 サンタリス ファーマ アー／エス ＨＩＦ−１ａ発現阻害のための強力なＬＮＡオリゴヌクレオチド

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
WO2001048190A2 (en) * 1999-12-23 2001-07-05 Exiqon A/S Therapeutic uses of lna-modified oligonucleotides
WO2003070918A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
KR20080023768A (ko) * 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
CN100523215C (zh) * 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
EP1386004A4 (en) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
EP1478656B1 (en) * 2002-02-01 2009-09-16 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
EP1857547B2 (en) * 2002-08-05 2020-12-02 Silence Therapeutics GmbH Further novel forms of interfering RNA molecules
AU2004221760B2 (en) * 2003-03-21 2010-03-18 Roche Innovation Center Copenhagen A/S Short interfering RNA (siRNA) analogues
WO2005073378A1 (en) * 2004-01-30 2005-08-11 Santaris Pharma A/S MODIFIED SHORT INTERFERING RNA (MODIFIED siRNA)
ES2556128T3 (es) * 2006-03-23 2016-01-13 Roche Innovation Center Copenhagen A/S ARN interfiriente pequeño internamente segmentado

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008518608A (ja) * 2004-11-09 2008-06-05 サンタリス ファーマ アー／エス ＨＩＦ−１ａ発現阻害のための強力なＬＮＡオリゴヌクレオチド

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6012025542; Ｂｉｏｃｈｅｍｉｓｔｒｙ Ｖｏｌ．４２, 2003, ｐ．７９６７-７９７５ *
JPN6012025544; Ｂｉｏｏｒｇ．　Ｍｅｄ．　Ｃｈｅｍ．　Ｌｅｔｔ． Ｖｏｌ．８, 1998, ｐ．２２１９-２２２２ *
JPN6012025546; Ｎｕｃｌｅｉｃ　Ａｃｉｄｓ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．３１，　Ｎｏ．２１, 2003, ｐ．６３６５-６３７２ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018504380A (ja) * 2014-12-18 2018-02-15 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｒｅｖｅｒｓｉｒ（商標）化合物
JP2023018065A (ja) * 2014-12-18 2023-02-07 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｒｅｖｅｒｓｉｒ（商標）化合物
JP2024037841A (ja) * 2014-12-18 2024-03-19 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｒｅｖｅｒｓｉｒ（商標）化合物
US12241064B2 (en) 2014-12-18 2025-03-04 Alnylam Pharmaceuticals, Inc. REVERSIR™ compounds

Also Published As

Publication number Publication date
AU2007209481A1 (en) 2007-08-02
WO2007085485A3 (en) 2007-09-13
US20090176977A1 (en) 2009-07-09
EP1984382A2 (en) 2008-10-29
WO2007085485A2 (en) 2007-08-02
EP1984382B1 (en) 2012-08-15
DK1984382T3 (da) 2012-09-03
AU2007209481B2 (en) 2012-01-12
CA2638837A1 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
EP1984382B1 (en) Lna modified phosphorothiolated oligonucleotides
ES2569558T3 (es) Composición farmacéutica que comprende oligonucleótidos antisentido anti-ARNmi
CN106795200B (zh) Galnac亚磷酰胺、其核酸缀合物及其用途
CN101821277B (zh) 四氢吡喃核酸类似物
US20080249039A1 (en) Modified Short Interfering Rna (Modified Sirna)
EP2970968B1 (en) Bridged bicyclic nucleosides
RU2740501C2 (ru) МОДИФИЦИРОВАННЫЕ ОЛИГОНУКЛЕОТИДЫ, АКТИВИРУЮЩИЕ РНКазу Н
WO2011115818A1 (en) 5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2635681A1 (en) Base modified oligonucleotides
EP3459962A1 (en) Tricyclic nucleosides and oligomeric compounds prepared therefrom
KR20250140080A (ko) 세포 프로그램된 사멸-리간드 1 유전자 발현을 억제하기 위한 siRNA, 이의 접합체 및 약학적 조성물과 용도
CN111448316A (zh) 新的硫代亚磷酰胺
WO2025188589A1 (en) NOVEL NUCLEOTIDES AND OLIGONUCLEOTIDES AND RNAi AGENTS COMPRISING THE SAME
CN119285688A (zh) 修饰的核苷酸单体及其用途
CN118813612A (zh) 一种化合物在RNAi药物中的应用
CA3130431A1 (en) Phosphonoacetate gapmer oligonucleotides
EP4477655A1 (en) Phenoxazine derivative and drug delivery system formulation using same
CN122038397A (zh) 一种化学修饰的siRNA分子及其应用
TW202604551A (zh) 用於治療ｂ型肝炎病毒之經修飾之反義寡核苷酸
WO2025148770A1 (zh) 修饰的核苷酸单体及其用途
CN113474352A (zh) 新型亚磷酰胺
JP2025529338A (ja) 炭素環ヌクレオシド、オリゴヌクレオチド及びその製造方法並びに医薬用途
WO2023167094A1 (ja) ５'位修飾ヌクレオシドおよびそれを用いたヌクレオチド
HK40060207A (en) Novel phosphoramidites
WO2021166981A1 (ja) 架橋型ヌクレオシドおよびそれを用いたヌクレオチド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120816

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121009